特利加压素治疗窦道阻塞综合征相关急性肾损伤：一种新的应用。

IF 3.9 2区医学 Q1 UROLOGY & NEPHROLOGY

Clinical Kidney Journal Pub Date : 2025-06-14 eCollection Date: 2025-07-01 DOI:10.1093/ckj/sfaf188

Callie J Meath, Bindu Simon, Rohtesh S Mehta, Partow Kebriaei, Jamie S Lin

{"title":"特利加压素治疗窦道阻塞综合征相关急性肾损伤：一种新的应用。","authors":"Callie J Meath, Bindu Simon, Rohtesh S Mehta, Partow Kebriaei, Jamie S Lin","doi":"10.1093/ckj/sfaf188","DOIUrl":null,"url":null,"abstract":"Sinusoidal obstruction syndrome (SOS) is a life-threatening complication of hematopoietic cell transplantation that can lead to multiorgan failure, including acute kidney injury (AKI) due to hepatorenal syndrome (HRS)-like physiology. Current supportive measures often fail in preserving renal function, and dialysis is associated with high mortality risk. Terlipressin, a vasopressin analog approved for HRS in cirrhosis, has not been previously described for SOS-AKI. We report the first detailed case of terlipressin improving renal function, restoring diuretic responsiveness, and preventing dialysis in a patient with SOS, highlighting its potential as a therapeutic option for SOS-related renal failure.","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":"18 7","pages":"sfaf188"},"PeriodicalIF":3.9000,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12259277/pdf/","citationCount":"0","resultStr":"{\"title\":\"Terlipressin for sinusoidal obstruction syndrome-associated acute kidney injury: a novel application.\",\"authors\":\"Callie J Meath, Bindu Simon, Rohtesh S Mehta, Partow Kebriaei, Jamie S Lin\",\"doi\":\"10.1093/ckj/sfaf188\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Sinusoidal obstruction syndrome (SOS) is a life-threatening complication of hematopoietic cell transplantation that can lead to multiorgan failure, including acute kidney injury (AKI) due to hepatorenal syndrome (HRS)-like physiology. Current supportive measures often fail in preserving renal function, and dialysis is associated with high mortality risk. Terlipressin, a vasopressin analog approved for HRS in cirrhosis, has not been previously described for SOS-AKI. We report the first detailed case of terlipressin improving renal function, restoring diuretic responsiveness, and preventing dialysis in a patient with SOS, highlighting its potential as a therapeutic option for SOS-related renal failure.\",\"PeriodicalId\":10435,\"journal\":{\"name\":\"Clinical Kidney Journal\",\"volume\":\"18 7\",\"pages\":\"sfaf188\"},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2025-06-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12259277/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Kidney Journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/ckj/sfaf188\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/7/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Kidney Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ckj/sfaf188","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

摘要

窦状窦阻塞综合征（SOS）是造血细胞移植的一种危及生命的并发症，可导致多器官功能衰竭，包括由肝肾综合征（HRS）样生理引起的急性肾损伤（AKI）。目前的支持措施往往不能保持肾功能，透析与高死亡率风险相关。特利加压素（Terlipressin）是一种抗利尿激素类似物，已被批准用于肝硬化HRS患者，但此前并未报道其用于SOS-AKI。我们报道了第一个详细的特利加压素改善肾功能，恢复利尿反应性和预防透析的病例，强调了它作为SOS相关肾衰竭的治疗选择的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Terlipressin for sinusoidal obstruction syndrome-associated acute kidney injury: a novel application.

Sinusoidal obstruction syndrome (SOS) is a life-threatening complication of hematopoietic cell transplantation that can lead to multiorgan failure, including acute kidney injury (AKI) due to hepatorenal syndrome (HRS)-like physiology. Current supportive measures often fail in preserving renal function, and dialysis is associated with high mortality risk. Terlipressin, a vasopressin analog approved for HRS in cirrhosis, has not been previously described for SOS-AKI. We report the first detailed case of terlipressin improving renal function, restoring diuretic responsiveness, and preventing dialysis in a patient with SOS, highlighting its potential as a therapeutic option for SOS-related renal failure.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical Kidney Journal Medicine-Transplantation

CiteScore

6.70

自引率

10.90%

发文量

242

审稿时长

8 weeks

期刊介绍： About the Journal Clinical Kidney Journal: Clinical and Translational Nephrology (ckj), an official journal of the ERA-EDTA (European Renal Association-European Dialysis and Transplant Association), is a fully open access, online only journal publishing bimonthly. The journal is an essential educational and training resource integrating clinical, translational and educational research into clinical practice. ckj aims to contribute to a translational research culture among nephrologists and kidney pathologists that helps close the gap between basic researchers and practicing clinicians and promote sorely needed innovation in the Nephrology field. All research articles in this journal have undergone peer review.